obesity drug news today glp-1 october 27 2025 2024 was a record year for trials and is already poised to take over FuturHealth: GLP-1s + Meals =

Despite the shared mechanisms of action, these clinical approaches vary considerably in development strategy and trial design

HRAs are funded entirely by your employer and governed by an employer-written plan document that can exclude weight-loss medications, require prior approval, or demand a Letter of Medical Necessity (LMN) before reimbursement

The development of long-acting incretin receptor agonists represents a huge step forward in the fight against the twin epidemics of type 2 diabetes mellitus and obesity

And unlike existing addiction medications, which are prescribed by specialists and remain vastly underused, GLP-1 drugs are already prescribed at enormous scale by primary care doctors

When introducing allulose, start with small amountstypically 510 grams per dayand gradually increase as tolerated